New RNA vaccine aims to stop breast cancer return
NCT ID NCT07652242
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-stage trial tests an investigational cancer vaccine called ITI-5000 in 60 people with stage II-III triple-negative breast cancer who have finished standard treatment. The vaccine uses self-amplifying RNA to teach the immune system to attack cancer cells. The study first finds a safe dose of the vaccine alone, then tests it combined with the immunotherapy drug pembrolizumab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ITI-5000 (self-amplifying RNA vaccine) and pembrolizumab
What this could lead to
If successful, this could lead to a new treatment option to prevent triple-negative breast cancer from coming back after standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so it is too soon to know if the vaccine works. There may be side effects from the vaccine or the combination with pembrolizumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Email: •••••@•••••
Contact